Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination

Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 21, Issue 2, 2007, Pages 173-191

  Köhrle, Josef ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

bile acid; deiodinase; diabetes; feedback regulation; hypothalamic regulation; insulin resistance; iodothyronine; selenoprotein; sulfation; T3 transporter; thermogenesis; thyronamine; TSH set point

Indexed keywords

BILE ACID; DEIODINASE 1; DEIODINASE 2; DEIODINASE 3; IODOTHYRONINE; LIOTHYRONINE; SELENOPROTEIN; THYROID HORMONE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

BIOAVAILABILITY; CELLULAR DISTRIBUTION; DEIODINATION; DIABETES MELLITUS; ENERGY METABOLISM; ENZYME LOCALIZATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HEMANGIOMA; HUMAN; HYPOTHALAMUS; INSULIN RESISTANCE; LIOTHYRONINE SYNTHESIS; MESOTHELIOMA; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TANYCYTE; THERMOREGULATION; THYROID CANCER; THYROID HORMONE BLOOD LEVEL; THYROID HORMONE METABOLISM; THYROID HORMONE RELEASE; THYROTROPIN BLOOD LEVEL;

ANIMALS; BILE ACIDS AND SALTS; CARRIER PROTEINS; CELL COMMUNICATION; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION REGULATION; HUMANS; HYPOTHALAMUS; IODIDE PEROXIDASE; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, THYROID HORMONE; THYROID HORMONES;

EID: 34249989901     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.04.001     Document Type: Review

References (100)

1. Yen P.M., Ando S., Feng X., et al. Thyroid hormone action at the cellular, genomic and target gene levels. Molecular and Cellular Endocrinology 246 (2006) 121-127
2. Psarra A.M.G., Solakidi S., and Sekeris C.E. The mitochondrion as a primary site of action of steroid and thyroid hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells. Molecular and Cellular Endocrinology 246 (2006) 21-33
3. Silva J.E. Thermogenic mechanisms and their hormonal regulation. Physiological Reviews 86 (2006) 435-464
4. Mousa S.A., O'Connor L., Davis F.B., et al. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (ditpa) is initiated at the cell surface and is integrin mediated. Endocrinology 147 (2006) 1602-1607
5. Farwell A.P., Dubord-Tomasetti S.A., Pietrzykowski A.Z., et al. Dynamic non-genomic actions of thyroid hormone in the developing rat brain. Endocrinology 147 (2006) 2567-2574
6. Hart M.E., Suchland K.L., Miyakawa M., et al. Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. Journal of Medicinal Chemistry 49 (2006) 1101-1112
7. Chiellini G., Frascarelli S., Ghelardoni S., et al. Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. The FASEB Journal 21 (2007) 1597-1608
8. Dunn J.T., and Dunn A.D. Update on intrathyroidal iodine metabolism. Thyroid 11 (2001) 407-414
9. Köhrle J., Jakob F., Contempré B., et al. Selenium, the thyroid, and the endocrine system. Endocrine Reviews 26 (2005) 944-984
10. Kohrle J. Selenium and the control of thyroid hormone metabolism. Thyroid 15 (2005) 841-853
11. Beckett G.J., Beech S., Nicol F., et al. Species differences in thyroidal iodothyronine deiodinase expression and the effect of selenium deficiency on its activity. Journal of Trace Elements and Electrolytes in Health and Disease 7 (1993) 123-124
12. Maia A.L., Kim B.W., Huang S.A., et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. The Journal of Clinical Investigation 115 (2005) 2524-2533
13. Jakobs T., Schmutzler C., Meissner J., et al. The promotor of the human type I 5′-deiodinase gene: mapping of the transcription start site and identification of a DR+4 thyroid hormone responsive element. European Journal of Biochemistry 247 (1997) 288-297
14. Bianco A.C., and Kim B.W. Deiodinases: implications of the local control of thyroid hormone action. The Journal of Clinical Investigation 116 (2006) 2571-2579
15. Bianco A.C., Salvatore D., Gereben B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 23 (2002) 38-89
16. Ambroziak M., Pachucki J., Chojnowski K., et al. Pax-8 expression correlates with Type II 5′ deiodinase expression in thyroids from patients with Graves' disease. Thyroid 13 (2003) 141-148
17. Laurberg P. Iodothyronine secretion from perfused dog thyroid lobes after prolonged thyrotropin treatment in vivo. Endocrinology 109 (1981) 1560-1565
18. Selmi-Ruby S., and Rousset B. Analysis of the functional state of T3 nuclear receptors expressed in thyroid cells. Molecular and Cellular Endocrinology 119 (1996) 95-104
19. Friesema E.C., Jansen J., Heuer H., et al. Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8. Nature Clinical Practice. Endocrinology & Metabolism 2 (2006) 512-523
20. Leonard J.L., Visser T.J., and Leonard D.M. Characterization of the subunit structure of the catalytically active type I iodothyronine deiodinase. The Journal of Biological Chemistry 276 (2001) 2600-2607
21. Curcio-Morelli C., Gereben B., Zavacki A.M., et al. In vivo dimerization of Types 1, 2, and 3 iodothyronine selenodeiodinases. Endocrinology 144 (2003) 937-946
22. Leonard J.L., Simpson G., and Leonard D.M. Characterization of the protein dimerization domain responsible for assembly of functional selenodeiodinases. The Journal of Biological Chemistry 280 (2005) 11093-11100
23. Simpson G.I.C., Leonard D.M., and Leonard J.L. Identification of the key residues responsible for the assembly of selenodeiodinases. The Journal of Biological Chemistry 281 (2006) 14615-14621
24. Zeold A., Pormuller L., Dentice M., et al. Metabolic instability of type 2 deiodinase is transferable to stable proteins independently of subcellular localization. The Journal of Biological Chemistry 281 (2006) 31538-31543
25. Kuiper G.G., Klootwijk W., and Visser T.J. Expression of recombinant membrane-bound type I iodothyronine deiodinase in yeast. Journal of Molecular Endocrinology 34 (2005) 865-878
26. Montero-Pedrazuela A., Bernal J., and Guadano-Ferraz A. Divergent expression of type 2 deiodinase and the putative thyroxine- binding protein p29, in rat brain, suggests that they are functionally unrelated proteins. Endocrinology 144 (2003) 1045-1052
27. Köhrle J., Baur A., Winzer R., et al. Expression of type II 5′-deiodinase (5′DII) and plasma glutathione peroxidase (pGPx) in human thyroid. Endocrine Journal 47 Supplement (2000) 175
28. Ohba K., Yoshioka T., and Muraki T. Identification of two novel splicing variants of human type II iodothyronine deiodinase mRNA. Molecular and Cellular Endocrinology 172 (2001) 169-175
29. Kasahara T., Tsunekawa K., Seki K., et al. Regulation of iodothyronine deiodinase and roles of thyroid hormones in human coronary artery smooth muscle cells. Atherosclerosis 186 (2006) 207-214
30. Maeda A., Toyoda N., Yasuzawa-Amano S., et al. Type 2 deiodinase expression is stimulated by growth factors in human vascular smooth muscle cells. Molecular and Cellular Endocrinology 200 (2003) 111-117
31. Friesema E.C., Kuiper G.G., Jansen J., et al. Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. Molecular Endocrinology 20 (2006) 2761-2772
32. Nicoloff J.T., Lum S.M., Spencer C.A., et al. Peripheral autoregulation of thyroxine to triiodothyronine conversion in man. Hormone and Metabolic Research. Supplement Series 14 (1984) 74-79
33. Nguyen T.T., Chapa F., and DiStefano III J.J. Direct measurement of the contributions of type I and type II 5′-deiodinases to whole body steady state 3,5,3′-triiodothyronine production from thyroxione in the rat. Endocrinology 139 (1998) 4626-4633
34. Leonard J.L., and Köhrle J. Intracellular pathways of thyroid hormone metabolism. In: Braverman L.E., and Utiger R.D. (Eds). Werner and Ingbar's The Thyroid - A Fundamental and Clinical Text. 8th edn. (2000), J.B. Lippincott Company, Philadelphia 136-173
35. Schomburg L., Riese C., Michaelis M., et al. Synthesis and metabolism of thyroid hormones is preferentially maintained in selenium-deficient transgenic mice. Endocrinology 147 (2006) 1306-1313
36. Streckfuss F., Hamann I., Schomburg L., et al. Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels in mice. Biochemical and Biophysical Research Communications 337 (2005) 739-745
37. Chanoine J.P., Braverman L.E., Farwell A.P., et al. The thyroid gland is a major source of circulating T3 in the rat. The Journal of Clinical Investigation 91 (1993) 2709-2713
38. Köhrle J. Iodothyronine deiodinases. Methods in Enzymology 347 (2002) 125-167
39. Ziouzenkova O., Orasanu G., Sukhova G., et al. Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Molecular Endocrinology 21 (2007) 77-88
40. Kuiper G.G.J.M., Wassen F., Klootwijk W., et al. Molecular basis for the substrate selectivity of cat Type I iodothyronine deiodinase. Endocrinology 144 (2003) 5411-5421
41. Hatfield D.L., and Gladyshev V.N. How selenium has altered our understanding of the genetic code. Molecular and Cellular Biology 22 (2002) 3565-3576
42. Sun X., and Maquat L.E. Nonsense-mediated decay: assaying for effects on selenoprotein mRNAs. Methods in Enzymology 347 (2002) 49-57
43. Muller C., Wingler K., and Brigelius-Flohe R. 3′UTRs of glutathione peroxidases differentially affect selenium-dependent mRNA stability and selenocysteine incorporation efficiency. Biological Chemistry 384 (2003) 11-18
44. Riese C., Michaelis M., Mentrup B., et al. Selenium-dependent pre- and posttranscriptional mechanisms are responsible for sexual dimorphic expression of selenoproteins in murine tissues. Endocrinology 147 (2006) 5883-5892
45. Dumitrescu A.M., Liao X.H., Abdullah M.S., et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nature Genetics 37 (2005) 1247-1252
46. Curcio C., Baqui M.M., Salvatore D., et al. The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. The Journal of Biological Chemistry 276 (2001) 30183-30187
47. Kim B.W., Daniels G.H., Harrison B.J., et al. Overexpression of Type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 594-598
48. Köhrle J. Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by the type I 5′-deiodinase and the expression of thyroid hormone receptors and other thyroid-specific (de-)differentiation markers. Current Topics in Pathology 91 (1997) 83-116
49. Schmutzler C., and Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10 (2000) 393-406
50. Schmutzler C., Hoang-Vu C., Ruger B., et al. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. European Journal of Endocrinology 150 (2004) 547-556
51. Huang S.A., Fish S.A., Dorfman D.M., et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing Type 3 iodothyronine deiodinase. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 4457-4461
52. Draper N., and Stewart P.M. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. The Journal of Endocrinology 186 (2005) 251-271
53. Masuda S., Strugnell S.A., Knutson J.C., et al. Evidence for the activation of 1alpha-hydroxyvitamin D(2) by 25-hydroxyvitamin D-24-hydroxylase: Delineation of pathways involving 1alpha,24-dihydroxyvitamin D(2) and 1alpha,25-dihydroxyvitamin D(2). Biochimica et Biophysica Acta 1761 (2006) 221-234
54. Mindnich R., Moller G., and Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Molecular and Cellular Endocrinology 218 (2004) 7-20
55. Bookout A.L., Jeong Y., Downes M., et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126 (2006) 789-799
56. Qatanani M., Zhang J., and Moore D.D. Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 146 (2005) 995-1002
57. De Groot L.J. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 151-164
58. Boelen A., Wiersinga W.M., and Koehrle J. Contributions of cytokines to nonthyroidal illness. Current Opinion in Endocrinology and Diabetes 13 (2006) 444-450
59. Hesch R.D. The 'Low T3-Syndrome' (1981), Academic Press, London pp. 1-263
60. Peeters R.P., Debaveye Y., Fliers E., et al. Changes within the thyroid axis during critical illness. Critical Care Clinics 22 (2006) 41-55
61. Boelen A., Kwakkel J., Alkemade A., et al. Induction of type 3 deiodinase activity in inflammatory cells of mice with chronic local inflammation. Endocrinology 146 (2005) 5128-5134
62. Peeters R.P., Kester M.H., Wouters P.J., et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 6460-6465
63. Wu S.Y., Green W.L., Huang W.S., et al. Alternate pathways of thyroid hormone metabolism. Thyroid 15 (2005) 943-958
64. Angstwurm M.W.A., Schottdorf J., Schopohl J., et al. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Critical Care Medicine 27 (1999) 1807-1813
65. Fekete C., Singru P.S., Sarkar S., et al. Ascending brainstem pathways are not involved in lipopolysaccharide-induced suppression of thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus. Endocrinology 146 (2005) 1357-1363
66. Alkemade A., Friesema E.C., Kuiper G.G., et al. Novel neuroanatomical pathways for thyroid hormone action in the human anterior pituitary. European Journal of Endocrinology 154 (2006) 491-500
67. Baur A., Bauer K., Jarry H., et al. Effects of proinflammatory cytokines on anterior pituitary 5′- deiodinase type I and type II. The Journal of Endocrinology 167 (2000) 505-515
68. Boelen A., Kwakkel J., Platvoet-Ter Schiphorst M., et al. Contribution of interleukin-12 to the pathogenesis of non-thyroidal illness. Hormone and Metabolic Research 36 (2004) 101-106
69. Baur A., Buchfelder M., and Köhrle J. Expression of 5′-deiodinase enzymes in normal pituitaries and in various human pituitary adenomas. European Journal of Endocrinology 147 (2002) 263-268
70. Christoffolete M.A., Ribeiro R., Singru P., et al. Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. Endocrinology 147 (2006) 1735-1743
71. Boelen A., Kwakkel J., Wiersinga W.M., et al. Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. The Journal of Endocrinology 191 (2006) 707-714
72. Tannahill L.A., Visser T.J., McCabe C.J., et al. Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clinical Endocrinology 56 (2002) 735-743
73. Heuer H., Maier M.K., Iden S., et al. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone sensitive neuron populations. Endocrinology 146 (2005) 1701-1706
74. Bernal J. Role of monocarboxylate anion transporter 8 (MCT8) in thyroid hormone transport: answers from mice. Endocrinology 147 (2006) 4034-4035
75. Jakobs T.C., Mentrup B., Schmutzler C., et al. Proinflammatory cytokines inhibit the expression and function of human type I 5′-deiodinase in HepG2 hepatocarcinoma cells. European Journal of Endocrinology 146 (2002) 559-566
76. Koenig R.J. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 15 (2005) 835-840
77. Kwakkel J., Wiersinga W.M., and Boelen A. Differential involvement of nuclear factor-{kappa}B and activator protein-1 pathways in the interleukin-1{beta}-mediated decrease of deiodinase type 1 and thyroid hormone receptor {beta}1 mRNA. The Journal of Endocrinology 189 (2006) 37-44
78. Zeold A., Doleschall M., Haffner M.C., et al. Characterization of the nuclear factor-kappa B responsiveness of the human dio2 gene. Endocrinology 147 (2006) 4419-4429
79. Yu J., and Koenig R.J. Induction of type 1 iodothyronine deiodinase to prevent the nonthyroidal illness syndrome in mice. Endocrinology 147 (2006) 3580-3585
80. Forhead A.J., Curtis K., Kaptein E., et al. Developmental control of iodothyronine deiodinases by cortisol in the ovine fetus and placenta near term. Endocrinology 147 (2006) 5988-5994
81. Grarup N., Andersen M.K., Andreasen C.H., et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7,342 Danish whites. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 363-366
82. Mentuccia D., Thomas M.J., Coppotelli G., et al. The Thr92Ala deiodinase Type 2 (DIO2) variant is not associated with Type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid 15 (2005) 1223-1227
83. Canani L.H., Capp C., Dora J.M., et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3472-3478
84. Appelhof B.C., Peeters R.P., Wiersinga W.M., et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 6296-6299
85. Eisenberg M., Samuels M., and DiStefano III J.J. L-T4 bioequivalence and hormone replacement studies via feedback control simulations. Thyroid 16 (2006) 1279-1292
86. Peeters R.P., van der Deure W.M., and Visser T.J. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. European Journal of Endocrinology 155 (2006) 655-662
87. Brabant G., Beck-Peccoz P., Jarzab B., et al. Is there a need to redefine the upper normal limit of TSH?. European Journal of Endocrinology 154 (2006) 633-637
88. Volzke H., Alte D., Kohlmann T., et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 15 (2005) 279-285
89. Weitzel J.M., Iwen K.A., and Seitz H.J. Regulation of mitochondrial biogenesis by thyroid hormone. Quarterly Journal of Experimental Physiology 88 (2003) 121-128
90. Barker S.B., and Klitgaard H.M. Metabolism of tissues excised from thyroxine-injected rats. The American Journal of Physiology 170 (1952) 81-86
91. Hansen J.B., and Kristiansen K. Regulatory circuits controlling white versus brown adipocyte differentiation. The Biochemical Journal 398 (2006) 153-168
92. Cinti S. The role of brown adipose tissue in human obesity. Nutrition, Metabolism and Cardiovascular Diseases 16 (2006) 569-574
93. Watanabe M., Houten S.M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006) 484-489
94. Lechan R.M., and Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. In: Kalsbeek A. (Ed). Progress in Brain Research Hypothalamic Integration of Energy Metabolism, Proceedings of the 24th International Summer School of Brain Research, held at the Royal Netherlands Academy of Arts and Sciences vol. 153 (2006), Elsevier pp. 209-235
95. Fliers E., Alkemade A., Wiersinga W.M., et al. Hypothalamic thyroid hormone feedback in health and disease. In: Kalsbeek A. (Ed). Progress in Brain Research Hypothalamic Integration of Energy Metabolism, Proceedings of the 24th International Summer School of Brain Research, held at the Royal Netherlands Academy of Arts and Sciences vol. 153 (2006), Elsevier pp. 189-207
96. Jakobs T.C., Koehler M.R., Schmutzler C., et al. Structure of the human Type I iodothyronine 5′-deiodinase gene and localization to chromosome 1p32-p33. Genomics 42 (1997) 361-363
97. Celi F.S., Canettieri G., Mentuccia D., et al. Structural organization and chromosomal localization of the human type II deiodinase gene. European Journal of Endocrinology 143 (2000) 267-271
98. Hernandez A., Park J.P., Lyon G.J., et al. Localization of the type 3 iodothyronine deiodinase (DIO3) gene to human chromosome 14q32 and mouse chromosome 12F1. Genomics 53 (1998) 119-121
99. Kim S.W., Hong S.J., Kim K.M., et al. A Novel cell type-specific mechanism for thyroid hormone-dependent negative regulation of the human type 1 deiodinase gene. Molecular Endocrinology 18 (2004) 2924-2936
100. Hernandez A., and St.Germain D.L. Activity and response to serum of the mammalian thyroid hormone deiodinase 3 gene promoter: identification of a conserved enhancer. Molecular and Cellular Endocrinology 206 (2003) 23-32